Navigation Links
FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
Date:7/29/2013

of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2012 which is on file with the SEC and available on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results.  There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda.  Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein.  Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf.  The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

[1] U.S. Department of Health and Human Services Food and Drug Administration, "Draft Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics" June 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf [Last accessed June 22, 2013]


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
2. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
3. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
4. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
5. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
6. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
7. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
8. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
9. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
10. EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications
11. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... H. Burbank , Chief Executive Officer, and Mathew Towse ... Annual Canaccord Genuity Growth Conference being held at the ... August 13 th at 4:30 p.m. ET.  A webcast ... .  About NxStage Medical NxStage ...
(Date:8/1/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... financial results for the second quarter ended June ... to see encouraging advancements in the US commercialization ... estimated total prescriptions and estimated total per week ... Arena,s President and Chief Executive Officer. "Other recent ...
(Date:7/31/2014)... Surgical Company (NASDAQ: STAA ) a leading ... systems for the eye today reported revenue for the ... a 10% increase over $18.2 million reported for the ... revenues grew 11% during the second quarter of 2014 ... of foreign currency exchange reduced sales by $0.1 million ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25
... 30 Aethlon Medical, Inc. (OTC Bulletin Board: ... devices to address infectious disease and cancer, announced today ... in the establishment of federal partnerships that advance biodefense, ... Hemopurifier®. The Aethlon Hemopurifier® is the first medical device ...
... 30 Covance Inc. (NYSE: CVD ) ... (EURONEXT: SAN and NYSE: SNY ) for ... ten years, Covance expects to provide drug development services ... billion to $2.2 billion.  Sanofi-aventis will sell their Porcheville, ...
Cached Medicine Technology:Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 2Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 3Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 4Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships 5Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance 2Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance 3
(Date:8/1/2014)... York (PRWEB) August 01, 2014 ... the wake of the 2012 Rejuvenate and ABG ... forward in New Jersey’s Bergen County Superior Court, ... in the proceeding, the Court has issued ... governing any and all hard copy and electronic ...
(Date:8/1/2014)... 2014 Summer is here, and with it ... the summer, and they can be a pain for dogs. ... help all their customers get rid of ticks and prevent ... eggs in the summer, which is why they are so ... grass and woodland areas and carry a number of diseases, ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... (D-CA), Gregg Harper (R-MS), and Peter Welch (D-VT), ... the Medicare Telehealth Parity Act of 2014, which ... support this effort to improve healthcare access and ... executive officer of ATA. "These cost-saving provisions are ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... others such as Zinc Oxide, Titanium Dioxide, and ... Building & Construction, Food & Beverages, Textiles, and ... ROW) - Global Trends and Forecasts to 2018" ... market drivers, opportunities, and trends in the diverse ...
(Date:8/1/2014)... August 01, 2014 The North America ... security solutions market in North America with analysis and ... from around $3.53 billion in 2014 to $4.77 billion ... to 2019. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... With the economic crisis facing this nation, hospitals are ... many companies offering various services and ideas on how ... efforts on the front-end registration process, dealing with eligibility ... All these procedures are important and are a good ...
... Corp. (Nasdaq: WBMD ), the leading provider ... announced a long-term strategic relationship with Boots UK Limited, ... United Kingdom, to jointly develop a consumer health and ... offering will leverage WebMD,s online consumer health assets and ...
... consumers are turning to webLAB to save time and money by ... today announced that consumers can now store, track and trend their ... an open, Web-based platform designed to empower consumers by putting them ... ...
... maintaining recommendation in support of LCA,s current board, urges ... (Nasdaq: LCAV ) announces that RiskMetrics Group,s ... its recommendation that LCA-Vision stockholders vote to retain ... proposals, including the removal of the current Directors and ...
... /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the ... that the first patient has been dosed in ... combination with a proprietary Lilly GLP-1 analogue, in ... a randomized, double-blind, placebo-controlled study in approximately 140 ...
... Medical images are increasingly becoming digitised. However, ... poses an immense challenge in terms of ... that image archive storage solution providers, picture ... image modality manufacturers become aware of the ...
Cached Medicine News:Health News:OCExaminer Gives More Cash to Hospitals 2Health News:OCExaminer Gives More Cash to Hospitals 3Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 2Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 3Health News:PWN Announces That Consumers Can Now Store webLAB Test Results In Their Microsoft HealthVault Account 2Health News:PWN Announces That Consumers Can Now Store webLAB Test Results In Their Microsoft HealthVault Account 3Health News:RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group 2Health News:RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group 3Health News:Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes 2Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 2Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 3Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 4
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With cast aluminum ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With tubular ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
Medicine Products: